Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Recruiting · NCT05687136 · Registry updated 2026-08-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 | 2026-08-24 | NCT05687136 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York | United States | 188 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |
| National Cancer Institute Developmental Therapeutics Clinic | Bethesda | United States | 28 |
| National Institutes of Health Clinical Center | Bethesda | United States | 800 |
| NYU Langone Hospital - Long Island | Mineola | United States | 107 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |